tiprankstipranks
Biogen (BIIB)
NASDAQ:BIIB
Holding BIIB?
Track your performance easily

Biogen (BIIB) Stock Forecast & Price Target

4,583 Followers
See the Price Targets and Ratings of:

BIIB Analyst Ratings

Moderate Buy
25Ratings
14 Buy
11 Hold
0 Sell
Based on 25 analysts giving stock ratings to
Biogen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BIIB Stock 12 Month Forecast

Average Price Target

$247.59
▲(56.80% Upside)
Based on 25 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $247.59 with a high forecast of $315.00 and a low forecast of $180.00. The average price target represents a 56.80% change from the last price of $157.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"172":"$172","208":"$208","244":"$244","280":"$280","316":"$316"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":315,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$315.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":247.59,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$247.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$180.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[172,208,244,280,316],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,173.79,184.6523076923077,195.51461538461538,206.37692307692308,217.23923076923077,228.10153846153847,238.96384615384613,249.82615384615383,260.6884615384615,271.5507692307692,282.4130769230769,293.2753846153846,304.1376923076923,{"y":315,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,173.79,179.46692307692308,185.14384615384614,190.82076923076923,196.49769230769232,202.17461538461538,207.85153846153847,213.52846153846156,219.20538461538462,224.88230769230768,230.55923076923077,236.23615384615385,241.91307692307691,{"y":247.59,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,173.79,174.2676923076923,174.7453846153846,175.22307692307692,175.70076923076923,176.17846153846153,176.65615384615384,177.13384615384615,177.61153846153846,178.08923076923077,178.56692307692308,179.04461538461538,179.5223076923077,{"y":180,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":231.95,"date":1700784000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":234.64,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":257.88,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.72,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220.95,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.87,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":217.51,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.43,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.65,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.66,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":200.81,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.68,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.79,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$315.00Average Price Target$247.59Lowest Price Target$180.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright
$300
Buy
89.99%
Upside
Reiterated
10/31/24
Biogen's Promising Pharmaceutical Prospects: Buy Rating Backed by Lecanemab Success and Pipeline Diversification
Oppenheimer
$270$255
Buy
61.49%
Upside
Reiterated
10/31/24
Oppenheimer Keeps Their Buy Rating on Biogen (BIIB)
Leerink Partners
$310$290
Buy
83.66%
Upside
Reiterated
10/31/24
Biogen (BIIB) PT Lowered to $290 at Leerink PartnersLeerink Partners analyst Marc H. Goodman lowered the price target on Biogen (NASDAQ: BIIB) to $290.00 (from $310.00) while maintaining a Outperform rating.
Barclays
$190$180
Hold
14.00%
Upside
Reiterated
10/31/24
Barclays Sticks to Its Hold Rating for Biogen (BIIB)
Bank of America Securities
$250
Hold
58.33%
Upside
Reiterated
10/31/24
Cautious Neutrality: Biogen's Mixed Performance and Uncertain Growth Outlook

Best Analysts Covering Biogen

Which Analyst Should I Follow If I Want to Buy BIIB and Sell After:
1 Month
xxx
Success Rate
15/33 ratings generated profit
45%
Average Return
+0.23%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 45.45% of your transactions generating a profit, with an average return of +0.23% per trade.
3 Months
xxx
Success Rate
16/33 ratings generated profit
48%
Average Return
-1.01%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 48.48% of your transactions generating a profit, with an average return of -1.01% per trade.
1 Year
Marc GoodmanLeerink Partners
Success Rate
11/38 ratings generated profit
29%
Average Return
-6.77%
reiterated a buy rating 25 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 28.95% of your transactions generating a profit, with an average return of -6.77% per trade.
2 Years
xxx
Success Rate
11/43 ratings generated profit
26%
Average Return
-17.63%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 25.58% of your transactions generating a profit, with an average return of -17.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
2
3
5
14
15
Buy
34
31
30
29
17
Hold
8
8
11
18
20
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
44
42
46
61
52
In the current month, BIIB has received 32 Buy Ratings, 20 Hold Ratings, and 0 Sell Ratings. BIIB average Analyst price target in the past 3 months is $247.59.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is $3.42 with a range of $3.13 to $3.85. The previous quarter’s EPS was $4.08. BIIB beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.90% of the time in the same period. In the last calendar year BIIB has Outperformed its overall industry.
Next quarter’s earnings estimate for BIIB is $3.42 with a range of $3.13 to $3.85. The previous quarter’s EPS was $4.08. BIIB beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.90% of the time in the same period. In the last calendar year BIIB has Outperformed its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is $2.42B with a range of $2.24B to $2.52B. The previous quarter’s sales results were $2.38B. BIIB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.67% of the time in the same period. In the last calendar year BIIB has Underperformed its overall industry.
Next quarter’s sales forecast for BIIB is $2.42B with a range of $2.24B to $2.52B. The previous quarter’s sales results were $2.38B. BIIB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.67% of the time in the same period. In the last calendar year BIIB has Underperformed its overall industry.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen’s 12-month average price target is $247.59.
    What is BIIB’s upside potential, based on the analysts’ average price target?
    Biogen has 56.80% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BIIB a Buy, Sell or Hold?
          Biogen has a consensus rating of Moderate Buy which is based on 14 buy ratings, 11 hold ratings and 0 sell ratings.
            What is Biogen’s price target?
            The average price target for Biogen is $247.59. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $315.00 ,the lowest forecast is $180.00. The average price target represents 56.80% Increase from the current price of $157.9.
              What do analysts say about Biogen?
              Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 25 Wall Streets Analysts.
                How can I buy shares of BIIB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis